Biodesix, Inc.
BDSX
Positions held
Your positionsBDSX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $270.43M | Enterprise value | $312.23M | Trailing P/E | — | Forward P/E | -116.50 |
| PEG | — | Price / book | 29.56 | Beta | 0.55 | Dividend yield | 0.00% |
| Revenue growth | 34.2% | Earnings growth | — | Gross margin | 82.5% | Operating margin | -20.0% |
| Profit margin | -27.0% | ROE | -5.4% | ROA | -14.1% | Debt / equity | 7.85 |
| Current ratio | 2.85 | Free cash flow | -$10.89M | Analyst recommendation | strong_buy | Mean target | $37.33 |
| 52w high | $31.97 | 52w low | $5.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $26.9M | $25.6M | $28.8M | $21.8M | $20.0M | — |
| Op margin | -20.0% | -24.2% | -6.8% | -32.4% | -48.4% | — |
| Net income | -$7.3M | -$7.8M | -$4.0M | -$8.7M | -$11.5M | — |
| Gross margin | 82.1% | 83.5% | 83.0% | 81.1% | 79.9% | — |
| Gross profit | $22.0M | $21.4M | $23.9M | $17.7M | $16.0M | — |
| Operating income | -$5.4M | -$6.2M | -$2.0M | -$7.0M | -$9.7M | — |
- Revenue +5% vs prior quarter ($27M vs $26M).
- Gross margin 82% (was 83.5% prior quarter).
- Operating margin expanded to -20%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | — |
| Op margin | -31.4% | -48.0% | -84.1% | -132.2% | — |
| Net income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | — |
| Gross margin | 81.1% | 78.2% | 73.5% | 63.0% | — |
| Gross profit | $71.8M | $55.8M | $36.1M | $24.1M | — |
| Operating income | -$27.8M | -$34.3M | -$41.3M | -$50.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
2026-09-29 · Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative
2026-09-28 · Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
2026-09-24 · Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
2026-09-24 · Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
2026-09-18 · Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism
2026-09-14 · Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
2026-09-03 · Biodesix to Participate in Upcoming Investor Conferences
2026-08-31 · What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?
2026-08-31 · Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
2026-08-24 · PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
2026-08-13 · Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing
Price (daily)
Full chart · RSI · MACD · patterns